Navigation Links
Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings
Date:11/15/2012

? 153.1.4 Insulin and Insulin Analogs 163.1.5 Monoclonal Antibodies 193.1.6 TNF-? Inhibitors 203.2 Promising Drug Classes for Biobetter Therapies 213.2.1 Human Growth Hormone 213.3 Comparison of Biosimilars and Biobetters 234 Technology Analysis 264.1 Introduction 264.1.1 Host Cell 264.1.2 Glycosylation 274.1.3 PEGylation 284.1.4 Polysialylation 284.1.5 Fusion Protein 284.1.6 PASylation 284.1.7 HESylation 295 Challenges and Opportunities 305.1 Opportunities 305.1.1 Biobetter Therapies Gain Substantial Market Shares upon Launch 305.1.2 Higher Success Rates in the Development of Biobetter Therapies 305.2 Challenges 305.2.1 Uncertainty Surrounding the Implementation of the Affordable Care Act will Limit Patient Access to Biobetter Drugs 305.2.2 Growing Debts and the Slowing of the Economy will Drive Governmental Bodies and Healthcare Providers to Restrict the Use of Expensive Biobetter Therapies 315.2.3 Regulatory Policies in Emerging Economies such as China and India do not Provide Enough Protection for the Development of Biobetter Therapies 316 Pipeline Analysis 326.1 Introduction3 326.2 Human Growth Hormone 326.3 Erythropoietin 346.4 Granulocyte-colony Stimulating Factor 356.5 Interferon-? and Interferon-? 366.6 Insulin and Insulin Analogs 386.7 Monoclonal Antibodies 406.8 Promising Drugs 426.8.1 LB03002 - HGH 426.8.2 Degludec - Insulin Analog 426.8.3 Theracim - Monoclonal Antibody 436.8.4 Pertuzumab - Monoclonal Antibody 436.8.5 RG7159 - Monoclonal Antibody 447 The US Regulatory Environment and Approval Pathways 457.1 Introduction 457.2 Biobetter Therapies 457.3 Biosimilar Therapies 468 The EU Regulatory Environment and Approval Pathways 478.1 Introduction 478.2 Biobetter Therapies 478.3 Biosimilar Therapies 479 Japan Regulatory Environment and Approval Pathways 499.1 Biobetter Therapies 499.2 Biosimilar Therapies 5010 Australia Regulatory Environment and Approval Pathways 5110.1 Biobetter Therapies 5110.2 Biosimilar Therapies 5111 China Regulatory Environment and
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference
2. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
3. Regulus to Present at the Lazard Capital Markets Healthcare Conference
4. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
5. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
6. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
7. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
8. Kinase Inhibitors: Global Markets -- Focus on the U.S.
9. MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
10. MarketsandMarkets: Global Spine Surgery Devices Market Worth $14.8 Billion by 2017
11. MarketsandMarkets: World Sensors Market in Healthcare Applications is expected to reach $13.11 billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... the diuretic hydrochlorothiazide (HCTZ) in ... in significant additional blood pressure reductions compared to either drug alone ... or more, medicines - single-tablet combinations simplify treatment by reducing ... number of pills patients take, EAST ...
... Named ,Illinois Rising Stars, CHICAGO, Jan. 18 ... property law firms in the United States, is,pleased to ... "Illinois,Super Lawyers" for 2008 in a survey conducted by ... designated "Rising Stars" in,Illinois., Meredith Martin Addy, chair ...
... Jan. 18 Abbott (NYSE: ABT ),announced today ... for its fully automated HTLV-I/HTLV-II blood screening test,for use ... for use by,laboratories to screen individual donations of blood ... Type I and/or human T --,lymphotropic virus Type II ...
Cached Biology Technology:Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 3
(Date:7/11/2014)... evidence has demonstrated that transplantation of mesenchymal stem cells ... or mouse models of Alzheimer,s disease (AD) and improve ... ischemia. Few studies are reported on the therapeutic effect ... AD and on the effect on oxidative injury and ... Yan and her team, School of Life Sciences, Tsinghua ...
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2
... May 3, 2010-Conventional agriculture production relies heavily on fossil ... a low cost. However, the uncertain future of fossil ... energy efficiencies in other cropping systems. Most of ... of corn and soybean with heavy inputs of fertilizer, ...
... May 3, 2010 Genes interact in complex networks that ... through relationships. Researchers are now discovering how biological networks ... published today in Genome Research ( www.genome.org ), ... shedding light on how interactions go awry in disease. ...
... May 2 Scientists at the University of Pittsburgh School ... a catch of new mediators that not only can explain ... novel treatments for a host of diseases linked to inflammatory ... of Nature Chemical Biology . There is strong ...
Cached Biology News:Reducing fossil energy use on the farm 2Reducing fossil energy use on the farm 3MicroRNA network study implicates rewired interactions in cancer 2Pitt pharmacologists go on a molecular fishing trip and hook prize catch 2